Acute Myeloid Leukemia
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies,…
Date: 28th March 2024
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents,…
Date: 16th February 2024
iwAL 2023 Session IV: Transplantation and immunotherapies in AML: improving patient outcomes
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Date: 20th October 2023
iwAL 2023 Session III: The relevance of TP53 mutation in AML
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Date: 29th September 2023
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Date: 22nd September 2023
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Date: 15th September 2023
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP). Several mutations, including…
Date: 10th August 2023
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
Therapeutic agents for patients with myelodysplastic syndromes (MDS) are currently under active investigation in clinical trials. The management of cytopenias,…
Date: 31st May 2023
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 24th May 2023
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
Allogeneic stem cell transplantation (alloSCT) remains a valuable treatment option for fit patients with acute myeloid leukemia (AML), and the…
Date: 5th April 2023
Managing and treating GvHD and other post-transplant complications
Graft-versus-host disease (GvHD) is a common complication associated with allogeneic stem cell transplantation (alloSCT), and can occur in acute and…
Date: 23rd February 2023
Novel immune therapies in MDS and challenges in this space
Myelodysplastic syndromes (MDS) represent a group of heterogeneous diseases which remain a challenge to treat, and several novel therapies are…
Date: 7th February 2023
